Project Grant R21TR005029
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$288K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a $198,750 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to the University of Pittsburgh to develop innovative graph deep learning models that can leverage spatially resolved single-cell transcriptomics data. The goal is to create computational tools that can identify tissue structures and pathologies, and uncover the underlying spatial cellular and molecular signatures associated with pathologies,...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $775,888 to the La Jolla Institute for Immunology (LJI) to create and validate a modular CRISPR-ready HLA transgenic mouse platform. The goal is to generate a versatile mouse model that can be readily engineered to express specific HLA class I and II alleles, enabling researchers to study human T cell responses for a broad range of diseases from infection to...
The National Institutes of Health Office of the Director awarded a $2,925,000 Project Grant to The Trustees of the University of Pennsylvania under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2022 for a three-year period ending August 31, 2025. The grant will fund research to develop an in-depth understanding of transcriptional and epigenetic reprogramming of neutrophils in the tumor microenvironment. The grantee will leverage single-cell profiling, fate mapping, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research at the University of Pittsburgh to identify post-translationally modified (PTM) protein antigens that alter immunogenicity and play a role in diseases like rheumatoid arthritis, type 1 diabetes, and cancer. The $183,701 award, effective from April 2, 2025 to March 31, 2027, will support the development of a robust, scalable platform...
This $1,383,800 federal Project Grant award from the Department of Health and Human Services' National Institutes of Health, under the Trans-NIH Research Support (CFDA 93.310) program, supports the University of Pittsburgh's research to develop new methods for creating and testing developmental signaling patterns. The project aims to leverage high-throughput optogenetic manipulation to build libraries of paired data on developmental signaling patterns and resulting tissue structures. This...
The National Institutes of Health (NIH) awarded a $1,710,000.00 Project Grant to the Salk Institute for Biological Studies in La Jolla, California under the Trans-NIH Research Support program (CFDA 93.310). The purpose of this 3-year grant, effective September 22, 2023, is to develop novel tools and model systems to track the dynamic interactions between rapid signaling, stress and metabolic responses, transcriptional changes, epigenetic modifications, and genetic alterations that contribute...
The National Cancer Institute (NCI) awarded a $408,829 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh to develop positive allosteric modulators targeting the XCR1 chemokine receptor. The project aims to leverage XCR1 signaling to enhance the function of conventional dendritic cells and cytotoxic T-cell responses against tumors. Building on prior research, the University of Pittsburgh will utilize DNA-encoded library technology to identify small-molecule...
This federal Project Grant award in the amount of $243,840.00 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The grant is funding a research project led by the University of Pittsburgh that aims to develop an effective statistical inference framework to understand protein mutations and identify compensatory mutations that can restore normal protein function. The research approach combines...
This $752,456 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of innovative, user-friendly computational technologies for identifying new bioactive small molecules and improving their pharmacological properties. The University of Pittsburgh is the prime recipient, leveraging its expertise in drug discovery, protein modeling, and lead optimization to advance...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...